Table 3 Associations between DRRD, ISD and ERDP mutually adjusted and overall mortality by subgroups of BC survivors.

From: Dietary patterns related to biological mechanisms and survival after breast cancer diagnosis: results from a cohort study

  

HR (95%CI)

 

N cases (events)

DRRDa

ISDa

ERDPa

All breast cancer survivors

13,270 (2340)

0.92 (0.87–0.96)

1.06 (1.00–1.12)

0.97 (0.92–1.03)

Menopausal status at diagnosis

 Premenopausal

3070 (527)

0.97 (0.87–1.07)

0.95 (0.83–1.08)

0.94 (0.83–1.06)

 Postmenopausal

10,200 (1813)

0.91 (0.86–0.95)

1.09 (1.02–1.16)

0.99 (0.93–1.05)

 P-value for heterogeneityb

 

0.951

0.074

0.693

BMI

 Normal-weight

7612 (1193)

0.91 (0.85–0.97)

1.10 (1.01–1.20)

1.04 (0.96–1.12)

 Overweight- obesity

5452 (1113)

0.93 (0.87–1.00)

1.03 (0.95–1.12)

0.93 (0.86–1.01)

 P-value for heterogeneityb

 

0.950

0.773

0.104

Physical activity level

 Inactive

7393 (1468)

0.90 (0.85–0.96)

1.07 (0.99– 1.16)

1.00 (0.93–1.07)

 Active

5682 (837)

0.94 (0.87–1.01)

1.02 (0.92–1.12)

0.93 (0.85–1.02)

 P-value for heterogeneityb

 

0.716

0.970

0.464

Stage of tumour

 Metastatic (stage IV)

1777 (585)

0.89 (0.81–0.99)

1.17 (1.04–1.33)

1.02 (0.91–1.14)

 Non-metastatic

7834 (968)

0.95 (0.88–1.02)

1.02 (0.93–1.12)

0.99 (0.91–1.08)

 P-value for heterogeneityb

 

0.261

0.795

0.089

Non-metastatic tumours

 Stage Ic

1940 (108)

0.93 (0.74–1.18)

1.13 (0.85–1.50)

1.14 (0.87–1.50)

 Stage II

1593 (250)

0.95 (0.81–1.12)

0.99 (0.82–1.20)

0.90 (0.76–1.07)

 Stage III

303 (79)

1.17 (0.84–1.63)

0.82 (0.56–1.19)

0.93 (0.65–1.34)

 P-value for heterogeneityb

 

0.269

0.716

0.131

Oestrogen receptor status

 ER(+)

7500 (1071)

0.91 (0.85–0.97)

1.04 (0.95–1.13)

1.01 (0.93–1.09)

 ER(–)

1678 (426)

0.93 (0.84–1.05)

1.17 (1.01–1.34)

1.04 (0.91–1.19)

 P-value for heterogeneityb

 

0.764

0.402

0.244

Progesterone receptor status

 PR(+)

5072 (620)

0.88 (0.80–0.96)

1.14 (1.02–1.29)

0.98 (0.88–1.09)

 PR(-)

2612 (515)

0.92 (0.83–1.03)

1.08 (0.95–1.24)

1.07 (0.95–1.20)

 P-value for heterogeneityb

 

0.819

0.169

0.980

HER2 status

 HER2(+)

856 (166)

1.07 (0.87–1.31)

0.99 (0.78–1.25)

1.09 (0.86–1.36)

 HER2(–)

3587 (473)

0.88 (0.79–0.98)

1.12 (0.98– 1.28)

0.99 (0.87–1.12)

 P-value for heterogeneityb

 

0.956

0.631

0.934

  1. All models were stratified by country and menopausal status at diagnosis and adjusted for age at diagnosis, attained level of education, physical activity, body mass index, alcohol consumption reported at recruitment, smoking habit and intensity as cigarettes per day at recruitment, ever use of hormone for menopause at diagnosis, cancer stage at diagnosis, cancer grade, and tumour receptor status: ER, PR, HER2.
  2. BMI body mass index, HER2 human epidermal receptor status 2, HR, Hazard Ratio; CI, Confidence Interval; DRRD, Diabetes risk reduction diet; ISD, Inflammatory score of diet; ERDP, Oestrogen-related dietary pattern.
  3. aUsing the scores as residuals of multiple regression model including DRRD, ISD and ERDP.
  4. bP-values for heterogeneity by introducing interaction terms in the multivariable models between the dietary pattern and the variable containing the subgroups using likelihood ratio tests.
  5. cIn situ BC cases are not included in these analyses since they are only 14 with 1 single event (death).
Back to article page